IBDEI2U9 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47637,0)
 ;;=C91.A2^^209^2346^300
 ;;^UTILITY(U,$J,358.3,47637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47637,1,3,0)
 ;;=3^Mature B-Cell Leukemia Burkitt Type,In Relapse
 ;;^UTILITY(U,$J,358.3,47637,1,4,0)
 ;;=4^C91.A2
 ;;^UTILITY(U,$J,358.3,47637,2)
 ;;=^5001785
 ;;^UTILITY(U,$J,358.3,47638,0)
 ;;=C91.Z0^^209^2346^277
 ;;^UTILITY(U,$J,358.3,47638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47638,1,3,0)
 ;;=3^Lymphoid Leukemia NEC,Not in Remission
 ;;^UTILITY(U,$J,358.3,47638,1,4,0)
 ;;=4^C91.Z0
 ;;^UTILITY(U,$J,358.3,47638,2)
 ;;=^5001786
 ;;^UTILITY(U,$J,358.3,47639,0)
 ;;=C91.Z1^^209^2346^276
 ;;^UTILITY(U,$J,358.3,47639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47639,1,3,0)
 ;;=3^Lymphoid Leukemia NEC,In Remission
 ;;^UTILITY(U,$J,358.3,47639,1,4,0)
 ;;=4^C91.Z1
 ;;^UTILITY(U,$J,358.3,47639,2)
 ;;=^5001787
 ;;^UTILITY(U,$J,358.3,47640,0)
 ;;=C91.Z2^^209^2346^275
 ;;^UTILITY(U,$J,358.3,47640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47640,1,3,0)
 ;;=3^Lymphoid Leukemia NEC,In Relapse
 ;;^UTILITY(U,$J,358.3,47640,1,4,0)
 ;;=4^C91.Z2
 ;;^UTILITY(U,$J,358.3,47640,2)
 ;;=^5001788
 ;;^UTILITY(U,$J,358.3,47641,0)
 ;;=C91.90^^209^2346^280
 ;;^UTILITY(U,$J,358.3,47641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47641,1,3,0)
 ;;=3^Lymphoid Leukemia,Unspec,Not in Remission
 ;;^UTILITY(U,$J,358.3,47641,1,4,0)
 ;;=4^C91.90
 ;;^UTILITY(U,$J,358.3,47641,2)
 ;;=^5001780
 ;;^UTILITY(U,$J,358.3,47642,0)
 ;;=C91.91^^209^2346^279
 ;;^UTILITY(U,$J,358.3,47642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47642,1,3,0)
 ;;=3^Lymphoid Leukemia,Unspec,In Remission
 ;;^UTILITY(U,$J,358.3,47642,1,4,0)
 ;;=4^C91.91
 ;;^UTILITY(U,$J,358.3,47642,2)
 ;;=^5001781
 ;;^UTILITY(U,$J,358.3,47643,0)
 ;;=C91.92^^209^2346^278
 ;;^UTILITY(U,$J,358.3,47643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47643,1,3,0)
 ;;=3^Lymphoid Leukemia,Unspec,In Relapse
 ;;^UTILITY(U,$J,358.3,47643,1,4,0)
 ;;=4^C91.92
 ;;^UTILITY(U,$J,358.3,47643,2)
 ;;=^5001782
 ;;^UTILITY(U,$J,358.3,47644,0)
 ;;=C92.00^^209^2346^18
 ;;^UTILITY(U,$J,358.3,47644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47644,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47644,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,47644,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,47645,0)
 ;;=C92.01^^209^2346^17
 ;;^UTILITY(U,$J,358.3,47645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47645,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47645,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,47645,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,47646,0)
 ;;=C92.02^^209^2346^16
 ;;^UTILITY(U,$J,358.3,47646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47646,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47646,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,47646,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,47647,0)
 ;;=C92.10^^209^2346^88
 ;;^UTILITY(U,$J,358.3,47647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47647,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,47647,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,47647,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,47648,0)
 ;;=C92.11^^209^2346^89
 ;;^UTILITY(U,$J,358.3,47648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47648,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,47648,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,47648,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,47649,0)
 ;;=C92.12^^209^2346^90
 ;;^UTILITY(U,$J,358.3,47649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47649,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Relapse
